Bruno Carlos
Sangro Gómez-Acebo
Catedrático de Universidad
The Bristol-Myers Squibb Children's Hospital
Nuevo Brunswick, Estados UnidosPublicaciones en colaboración con investigadores/as de The Bristol-Myers Squibb Children's Hospital (6)
2024
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
2023
-
Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)
Clinical and Translational Science, Vol. 16, Núm. 8, pp. 1445-1457
-
Nivolumab Plus Cabozantinib with or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results from Cohort 6 of the CheckMate 040 Trial
Journal of Clinical Oncology
2022
-
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
The Lancet Oncology, Vol. 23, Núm. 1, pp. 77-90
2021
-
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
Journal of Hepatology, Vol. 75, Núm. 3, pp. 600-609
2017
-
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502